Stocks in play: Pharmadrug Inc
Provides an update on multiple activities currently underway which support the Company's 'pipeline-in-a-pill' approach in the development of PD-001, its patented, orally bioavailable version of cepharanthine for the treatment of cancer and infectious disease. Pharmadrug Inc shares C.PHRX are trading unchanged at $0.05.
Read:
The M&A Flurry That Started in 2021 Isn’t Even Close to Done, According to Analysts
Market Response to Oil and Gas Stocks Proving Energy Industry Can Still be ESG Friendly
ESG and RSG Ambitions Causing Shifting Tides in the Oil and Gas Industry’s M&A Scene
Big Takeovers Yielding Big Premiums on Acquisition Prices So Far in 2022